|
EVG/COBI/TDF/FTC
|
RAL
|
MVC
|
ATV
+/-
RTV |
PK Data |
↑ or ↓ EVG, COBI, ATV possible |
With unboosted ATV
RAL: AUC ↑ 72%
With (ATV 300 mg + RTV 100 mg) once daily
RAL: AUC ↑ 41%
|
With unboosted ATV
MVC: AUC ↑ 257%
With (ATV 300 mg + RTV 100 mg) once daily
MVC: AUC ↑ 388%
|
Dose |
Do not co-administer. |
Standard |
MVC 150 mg BID with ATV +/− RTV |
DRV
(always use with RTV) |
PK Data |
↑ or ↓ EVG, COBI, DRV possible |
With (DRV 600 mg + RTV 100 mg) BID
RAL: AUC ↓ 29% and Cmin ↑ 38% |
With (DRV 600 mg + RTV 100 mg) BID
MVC: AUC ↑ 305%
With (DRV 600 mg + RTV 100 mg) BID + ETR
MVC: AUC ↑ 210%
|
Dose |
Do not co-administer. |
Standard |
MVC 150 mg BID |
EFV |
PK Data |
↑ or ↓ EVG, COBI, EFV possible |
EFV: AUC ↓ 36% |
MVC: AUC ↓ 45% |
Dose |
Do not co-administer. |
Standard |
MVC 600 mg BID |
EVG/COBI/TDF/FTC |
PK Data |
•
|
No data |
↑ MVC possible |
Dose |
Do not co-administer. |
Do not co-administer. |
ETR |
PK Data |
↑ or ↓ EVG, COBI, ETR possible |
ETR: Cmin ↓ 17%
RAL: Cmin ↓ 34% |
MVC: AUC ↓ 53%, Cmax ↓ 60% |
Dose |
Do not co-administer. |
Standard |
MVC 600 mg BID in the absence of a potent CYP3A inhibitor |
FPV |
PK Data |
↑ or ↓ EVG, COBI, FPV possible |
No significant effect |
Unknown; ↑ MVC possible |
Dose |
Do not co-administer. |
Standard |
MVC 150 mg BID |
LPV/r |
PK Data |
↑ or ↓ EVG, COBI, LPV possible
RTV and COBI have similar effects on CYP3A.
|
↓ RAL
↔ LPV/r |
MVC: AUC ↑ 295%
With LPV/r + EFV
MVC: AUC ↑ 153%
|
Dose |
Do not co-administer. |
Standard |
MVC 150 mg BID |
NVP |
PK Data |
↑ or ↓ EVG, COBI, NVP possible |
No data |
MVC: AUC ↔ and Cmax ↑ 54% |
Dose |
Do not co-administer. |
Standard |
Without PI
MVC 300 mg BID
With PI (except TPV/r)
MVC 150 mg BID
|
RAL |
PK Data |
No data |
•
|
RAL: AUC ↓ 37%
MVC: AUC ↓ 21% |
Dose |
Do not co-administer. |
Standard |
RPV |
PK Data |
↑ or ↓ EVG, COBI, RPV possible |
No data |
No data |
Dose |
Do not co-administer. |
No data |
No data |
RTV |
PK Data |
↑ or ↓ EVG, COBI possible
RTV and COBI have similar effects on CYP3A.
|
With RTV 100 mg BID
RAL: AUC ↓ 16% |
With RTV 100 mg BID
MVC: AUC ↑ 161% |
Dose |
Do not co-administer. |
Standard |
MVC 150 mg BID |
SQV
(always use with RTV) |
PK Data |
↑ or ↓ EVG, COBI, SQV possible
RTV and COBI have similar effects on CYP3A.
|
No data |
With (SQV 1000 mg + RTV 100 mg) BID
MVC: AUC ↑ 877%
With (SQV 1000 mg + RTV 100 mg) BID + EFV
MVC: AUC ↑ 400%
|
Dose |
Do not co-administer. |
Standard |
MVC 150 mg BID |
TPV
(always use with RTV) |
PK Data |
↑ or ↓ EVG, COBI, TPV possible
RTV and COBI have similar effects on CYP3A.
|
With (TPV 500 mg +
RTV 200 mg) BID
RAL: AUC ↓ 24% |
With (TPV 500 mg + RTV 200 mg) BID
MVC: No significant change in AUC
TPV: No data |
Dose |
Do not co-administer. |
Standard |
MVC 300 mg BID |